Perspective Therapeutics (CATX) Finished Goods (2011 - 2023)

Perspective Therapeutics has disclosed Finished Goods across 11 years of filings, most recently posting $20000.0 for Q3 2023.

• Finished Goods for Q3 2023 came in at $20000.0, down 25.93% year-over-year; the trailing twelve-month figure through Sep 2023 was $20000.0 (down 25.93% YoY), and the FY2022 annual result was $21000.0, changed N/A from the prior year.
• Finished Goods came in at $20000.0 for Q3 2023 at Perspective Therapeutics, up from $18000.0 in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $49000.0 in Q2 2021 to a low of $7000.0 in Q4 2019.
• The 5-year median for Finished Goods is $21000.0 (2022), against an average of $22368.4.
• Across the five-year window, Finished Goods slumped 72.97% in 2019 and jumped 314.29% in 2021, its largest moves.
• Perspective Therapeutics' Finished Goods stood at $7000.0 in 2019, then changed by 0.0% to $7000.0 in 2020, then surged by 314.29% to $29000.0 in 2021, then fell by 27.59% to $21000.0 in 2022, then retreated by 4.76% to $20000.0 in 2023.
• The last three Finished Goods figures came in at $20000.0 (Q3 2023), $18000.0 (Q2 2023), and $15000.0 (Q1 2023), per Business Quant data.